Could cause temporary or reversible harm; serious harm is unlikely.
CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands |
| NDC | 82009-030-10 |
| Full product label | Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC: 82009-030-10 |
| Recalling firm | Breckenridge Pharmaceutical, Inc. |
| Distribution | AZ, IN, NJ |
| Quantity | 3,591 bottles |
| Recall initiated | 2025-08-08 |
| Report date | 2025-09-17 |
| Recall completed | — |
| Recall number | D-0621-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Berkeley Heights NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗